Neuron-specific enolase as a marker of the severity and outcome of hypoxic ischemic encephalopathy

• Published in: Brain & development (Tokyo. 1979) Vol. 26; no. 6; pp. 398 - 402
• Main Authors: Celtik, Coşkun, Acunaş, Betül, Oner, Naci, Pala, Ozer
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.09.2004
• Subjects: Asphyxia Neonatorum - blood; Asphyxia Neonatorum - diagnosis; Asphyxia Neonatorum - enzymology; Biomarkers - blood; Brain - enzymology; Brain - pathology; Brain - physiopathology; Disease Progression; Electroencephalography; Humans; Hypoxia-Ischemia, Brain - blood; Hypoxia-Ischemia, Brain - diagnosis; Hypoxia-Ischemia, Brain - enzymology; Hypoxic ischemic encephalopathy; Infant, Newborn; Neuron-specific enolase; Perinatal asphyxia; Phosphopyruvate Hydratase - blood; Predictive Value of Tests; Reproducibility of Results; Severity of Illness Index; Short-term outcome; Tomography, X-Ray Computed; Up-Regulation - physiology; Perinatal asphyxia; Hypoxic ischemic encephalopathy; Short-term outcome; Neuron-specific enolase
• ISSN: 0387-7604; 1872-7131
• DOI: 10.1016/j.braindev.2003.12.007

The aim of this study was to evaluate serum concentrations of neuron-specific enolase (NSE) as a marker of the severity of hypoxic ischemic encephalopathy (HIE) and to elucidate the relation among the concentrations of NSE, grade of HIE and short-term outcome. Forty-three asphyxiated full-term newborn infants who developed symptoms and signs of HIE (Group 1) and 29 full-term newborn infants with meconium-stained amniotic fluid but with normal physical examination (Group 2) were studied with serial neurological examination, Denver developmental screening test (DDST), electroencephalogram and computerized cerebral tomography (CT) for neurological follow-up. Thirty healthy infants were selected as the control group. In the patient groups, two blood samples were taken to measure NSE levels, one between 4 and 48 h and the other 5–7 days after birth. Serum NSE levels were significantly higher in infants with HIE compared to those infants in Group 2 and control group. The mean serum concentrations of the second samples decreased in all groups studied but they were significantly higher in Group 1 compared to those in Group 2. Serum NSE concentrations of initial samples were significantly higher in patients with stage III HIE than in those with stages II and I. The sensitivity and specificity values of serum NSE as a predictor of HIE of moderate or severe degree (cut-off value 40.0 μg/l) were 79 and 70%, respectively, and as a predictor of poor outcome (cut-off value 45.4 μg/l) were calculated as 84 and 70%, respectively. The predictive capacity of serum NSE concentrations for poor outcome seems to be better than predicting HIE of moderate or severe degree. However, earlier and/or CSF samples may be required to establish serum NSE as an early marker for the application of neuroprotective strategies.